| 1 |
33123903 | Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis. | 2020 Oct |
2 |
| 2 |
26754586 | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA₂ in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome. | 2016 Mar |
8 |
| 3 |
22679249 | Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. | 2013 Feb |
1 |
| 4 |
23174369 | Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. | 2013 Jan |
2 |
| 5 |
23819752 | Pitavastatin in cardiometabolic disease: therapeutic profile. | 2013 |
1 |
| 6 |
22472908 | Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. | 2012 Jul |
1 |
| 7 |
21446776 | Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. | 2011 |
1 |
| 8 |
22152282 | Pitavastatin: novel effects on lipid parameters. | 2011 Nov |
1 |
| 9 |
10428299 | NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. | 1999 Jul |
3 |